Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded German American Bancorp. from a buy rating to a hold rating in a research report on Tuesday, April 30th. Mizuho lifted their price objective on Microchip Technology from $95.00 to $100.00 and gave the company a buy rating in a research report on Thursday, May 9th. Wedbush lifted their price objective on Workday from $209.00 to $211.00 and gave the company a neutral rating in a research report on Wednesday, May 29th. ValuEngine raised Zynerba Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, May 17th. Finally, Stifel Nicolaus set a $154.00 price objective on argenx and gave the company a buy rating in a research report on Wednesday, May 22nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. Atara Biotherapeutics has a consensus rating of Buy and a consensus price target of $41.86.
Shares of NASDAQ:ATRA opened at $18.32 on Tuesday. The stock has a market capitalization of $848.58 million, a P/E ratio of -3.48 and a beta of 2.11. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96. Atara Biotherapeutics has a 52 week low of $17.69 and a 52 week high of $43.95. The firm has a fifty day simple moving average of $21.35.
In other news, Director Eric Dobmeier bought 2,000 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, June 27th. The shares were purchased at an average price of $19.50 per share, for a total transaction of $39,000.00. Following the completion of the acquisition, the director now owns 16,000 shares of the company’s stock, valued at $312,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joe Newell sold 1,500 shares of Atara Biotherapeutics stock in a transaction on Monday, May 6th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the transaction, the insider now owns 62,998 shares in the company, valued at approximately $2,204,930. The disclosure for this sale can be found here. Insiders sold 22,950 shares of company stock worth $641,147 in the last quarter. 7.00% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of ATRA. SG Americas Securities LLC lifted its stake in shares of Atara Biotherapeutics by 5.1% in the first quarter. SG Americas Securities LLC now owns 10,432 shares of the biotechnology company’s stock worth $415,000 after acquiring an additional 503 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Atara Biotherapeutics by 12.7% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,554 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 512 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Atara Biotherapeutics by 6.2% during the fourth quarter. Legal & General Group Plc now owns 16,809 shares of the biotechnology company’s stock valued at $584,000 after purchasing an additional 983 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Atara Biotherapeutics by 16.5% during the first quarter. Oppenheimer & Co. Inc. now owns 8,792 shares of the biotechnology company’s stock valued at $350,000 after purchasing an additional 1,247 shares during the last quarter. Finally, Manchester Capital Management LLC bought a new position in shares of Atara Biotherapeutics during the first quarter valued at approximately $56,000.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More: Why do commodities matter?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.